<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1688-0390</journal-id>
<journal-title><![CDATA[Revista Médica del Uruguay]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. Méd. Urug.]]></abbrev-journal-title>
<issn>1688-0390</issn>
<publisher>
<publisher-name><![CDATA[Sindicato Médico del Uruguay]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1688-03902024000401302</article-id>
<article-id pub-id-type="doi">10.29193/rmu.40.4.7</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Factor de crecimiento epidérmico recombinante humano en el tratamiento de la úlcera de pie diabético]]></article-title>
<article-title xml:lang="en"><![CDATA[Recombinant human epidermal growth factor in the treatment of diabetic foot ulcers]]></article-title>
<article-title xml:lang="pt"><![CDATA[Fator de crescimento epidérmico recombinante humano no tratamento da úlcera do pé diabético]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Orellano]]></surname>
<given-names><![CDATA[Pablo]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Irastorza]]></surname>
<given-names><![CDATA[Lorena]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Introini]]></surname>
<given-names><![CDATA[Lucia]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Torre]]></surname>
<given-names><![CDATA[Wendy]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidad de la República Unidad de Pie Diabético, Hospital de Clínicas Facultad de Medicina]]></institution>
<addr-line><![CDATA[Montevideo ]]></addr-line>
<country>Uruguay</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Hospital Regional Mercedes Servicio de Endocrinología Unidad de Pie Diabético]]></institution>
<addr-line><![CDATA[Soriano, Montevideo ]]></addr-line>
<country>Uruguay</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>00</month>
<year>2024</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>00</month>
<year>2024</year>
</pub-date>
<volume>40</volume>
<numero>4</numero>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.edu.uy/scielo.php?script=sci_arttext&amp;pid=S1688-03902024000401302&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.edu.uy/scielo.php?script=sci_abstract&amp;pid=S1688-03902024000401302&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.edu.uy/scielo.php?script=sci_pdf&amp;pid=S1688-03902024000401302&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen La herida del pie diabético es una complicación común y su tratamiento, una tarea desafiante. Alteraciones moleculares complejas generan disfunción celular de citoquinas y factores de crecimiento que retrasan la cicatrización de la úlcera. El factor de crecimiento epidérmico (FCE) juega un papel relevante; sin embargo, su biodisponibilidad está alterada. La investigación clínica sugiere que la aplicación de FCE recombinante humano (rhFCE) como adyuvante al tratamiento estándar puede lograr la curación parcial o completa y prevenir complicaciones.  Objetivo: Comunicar los resultados del tratamiento de la úlcera de pie diabético con rhFCE en 5 pacientes asistidos en la Unidad de Pie del Hospital Público.  Material y método: Estudio observacional, descriptivo y retrospectivo de los registros ambulatorios de pacientes diabéticos mayores de 18 años, con úlceras neuroisquémicas de al menos 4 semanas de retraso en la cicatrización, tratados con rhFCE intradérmico entre junio y diciembre del 2022. Fueron tratados 3 pacientes masculinos y 2 femeninos, con una media de edad e 57,8 años, con úlceras clasificadas como Texas IIA IIC y IIIA, IIIC, cuyo diámetro inicial fue de 38 cm2. Se realizó una media de 8 aplicaciones por paciente del rhFCE durante un promedio de 32 días.  Resultado: A las 8 semanas, el diámetro medio de la lesión se redujo a 8,2 cm2, con un porcentaje de reducción medio del 89%. El cierre total de la lesión se logró en los 5 pacientes, en 4 de ellos en ese período. Como efecto secundario, 3 pacientes presentaron dolor y 2, escalofríos. No hubo recidivas luego de un año de seguimiento pos cicatrización.  Conclusión: La aplicación del rhFCE en 5 pacientes con úlceras neuroisquémicas fue segura y logró la reparación tisular efectiva completa en 4 de ellos en el período de 8 semanas.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract Diabetic foot wounds are a common complication, and their treatment is a challenging task. Complex molecular alterations cause cellular dysfunction of cytokines and growth factors, which delay ulcer healing. Epidermal growth factor (EGF) plays a relevant role; however, its bioavailability is altered. Clinical research suggests that the application of recombinant human EGF (rhEGF) as an adjunct to standard treatment can achieve partial or complete healing and prevent complications.  Objective: To communicate the results of diabetic foot ulcer treatment with rhEGF in 5 patients attended at the Foot Unit of the Public Hospital.  Material and Method: An observational, descriptive, and retrospective study of outpatient records of diabetic patients over 18 years of age, with neuroischemic ulcers that had been delayed in healing for at least 4 weeks, treated with intradermal rhEGF between June and December 2022. Three male and two female patients were treated, with an average age of 57,8 years, with ulcers classified as Texas IIA, IIC, IIIA, and IIIC, with an initial diameter of 38 cm2. An average of 8 applications per patient of rhEGF were performed over an average of 32 days.  Results: At 8 weeks, the mean diameter of the lesion was reduced to 8,2 cm2, with an average reduction percentage of 89%. Total closure of the lesion was achieved in all 5 patients, with 4 of them achieving this within the same period. As a side effect, 3 patients experienced pain and 2 experienced chills. There were no recurrences after one year of post-healing follow-up.  Conclusion: The application of rhEGF in 5 patients with neuroischemic ulcers was safe and achieved effective complete tissue repair in 4 of them within 8 weeks.]]></p></abstract>
<abstract abstract-type="short" xml:lang="pt"><p><![CDATA[Resumo A ferida do pé diabético é uma complicação comum, e seu tratamento é uma tarefa desafiadora. Alterações moleculares complexas causam disfunção celular de citocinas e fatores de crescimento, o que retarda a cicatrização da úlcera. O fator de crescimento epidérmico (FCE) desempenha um papel relevante; no entanto, sua biodisponibilidade está alterada. A pesquisa clínica sugere que a aplicação de FCE recombinante humano (rhFCE) como adjuvante ao tratamento padrão pode alcançar a cura parcial ou completa e prevenir complicações.  Objetivo: Comunicar os resultados do tratamento da úlcera de pé diabético com rhFCE em 5 pacientes atendidos na Unidade de Pé do Hospital Público.  Material e método: Estudo observacional, descritivo e retrospectivo dos registros ambulatoriais de pacientes diabéticos maiores de 18 anos, com úlceras neuroisquêmicas com atraso na cicatrização de pelo menos 4 semanas, tratados com rhFCE intradérmico entre junho e dezembro de 2022. Foram tratados 3 pacientes do sexo masculino e 2 do sexo feminino, com uma média de idade de 57,8 anos, com úlceras classificadas como Texas IIA, IIC, IIIA e IIIC, com um diâmetro inicial de 38 cm2. Foi realizada uma média de 8 aplicações por paciente de rhFCE durante uma média de 32 dias.  Resultado: Após 8 semanas, o diâmetro médio da lesão foi reduzido para 8,2 cm2, com uma redução média de 89%. O fechamento total da lesão foi alcançado em todos os 5 pacientes, sendo que 4 deles obtiveram isso no mesmo período. Como efeito colateral, 3 pacientes apresentaram dor e 2 apresentaram calafrios. Não houve recidivas após um ano de acompanhamento pós cicatrização.  Conclusão: A aplicação de rhFCE em 5 pacientes com úlceras neuroisquêmicas foi segura e obteve reparação tecidual completa eficaz em 4 deles no período de 8 semanas.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Pie diabético]]></kwd>
<kwd lng="es"><![CDATA[Factor de crecimiento epidérmico recombinante humano]]></kwd>
<kwd lng="es"><![CDATA[Heberprot-P]]></kwd>
<kwd lng="es"><![CDATA[Ulcera de pie diabético]]></kwd>
<kwd lng="es"><![CDATA[Cicatrización de heridas]]></kwd>
<kwd lng="en"><![CDATA[Diabetic foot]]></kwd>
<kwd lng="en"><![CDATA[Recombinant human epidermal growth factor]]></kwd>
<kwd lng="en"><![CDATA[Heberprot-P]]></kwd>
<kwd lng="en"><![CDATA[Diabetic foot ulcer]]></kwd>
<kwd lng="en"><![CDATA[Wound healing]]></kwd>
<kwd lng="pt"><![CDATA[Pé diabético]]></kwd>
<kwd lng="pt"><![CDATA[Fator de crescimento epidérmico recombinante humano]]></kwd>
<kwd lng="pt"><![CDATA[Heberprot-P]]></kwd>
<kwd lng="pt"><![CDATA[Úlcera de pé diabético]]></kwd>
<kwd lng="pt"><![CDATA[Cicatrização de feridas]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1.</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Piaggesi]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Apelqvist]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Piaggesi]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Apelqvist]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<source><![CDATA[The diabetic foot syndrome]]></source>
<year>2018</year>
<publisher-loc><![CDATA[Pisa, Lund ]]></publisher-loc>
<publisher-name><![CDATA[Karger]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B2">
<label>2.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yazdanpanah]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Nasiri]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Adarvishi]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Literature review on the management of diabetic foot ulcer]]></article-title>
<source><![CDATA[World J Diabetes]]></source>
<year>2015</year>
<volume>6</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>37-53</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Patel]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Srivastava]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Singh]]></surname>
<given-names><![CDATA[MR]]></given-names>
</name>
<name>
<surname><![CDATA[Singh]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Mechanistic insight into diabetic wounds: Pathogenesis, molecular targets and treatment strategies to pace wound healing]]></article-title>
<source><![CDATA[Biomed Pharmacother]]></source>
<year>2019</year>
<volume>112</volume>
<numero>108615</numero>
<issue>108615</issue>
<page-range>108615</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Portero-Otín]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Pamplona]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Bellmunt]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Ruíz]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
<name>
<surname><![CDATA[Prat]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Salvayre]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Advanced glycation end product precursors impair epidermal growth factor receptor signaling]]></article-title>
<source><![CDATA[Diabetes]]></source>
<year>2002</year>
<volume>51</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>1535-42</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Hu]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Diao]]></surname>
<given-names><![CDATA[Q]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Miao]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Therapeutic effect of the epidermal growth factor on diabetic foot ulcer and the underlying mechanisms]]></article-title>
<source><![CDATA[Exp Ther Med]]></source>
<year>2019</year>
<volume>17</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>1643-8</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Schaper]]></surname>
<given-names><![CDATA[NC]]></given-names>
</name>
<name>
<surname><![CDATA[van Netten]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
<name>
<surname><![CDATA[Apelqvist]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Bus]]></surname>
<given-names><![CDATA[SA]]></given-names>
</name>
<name>
<surname><![CDATA[Fitridge]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Game]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Practical guidelines on the prevention and management of diabetes-related foot disease (IWGDF 2023 update)]]></article-title>
<source><![CDATA[Diabetes Metab Res Rev]]></source>
<year>2024</year>
<volume>40</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>e3657</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Orellano]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Torres Negreira]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Colombo]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Lamela]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Saliwonczyk]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Berro]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Experiencia con el uso de plasma rico en plaquetas autólogo en el tratamiento de las úlceras del pie diabético]]></article-title>
<source><![CDATA[Rev Med Urug]]></source>
<year>2021</year>
<volume>37</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>e201</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Martí-Carvajal]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
<name>
<surname><![CDATA[Gluud]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Nicola]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Simancas-Racines]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Reveiz]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Oliva]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Growth factors for treating diabetic foot ulcers]]></article-title>
<source><![CDATA[Cochrane database Syst Rev]]></source>
<year>2015</year>
<volume>10</volume>
<numero>10</numero>
<issue>10</issue>
</nlm-citation>
</ref>
<ref id="B9">
<label>9.</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Han]]></surname>
<given-names><![CDATA[S-K]]></given-names>
</name>
</person-group>
<source><![CDATA[Innovations and advances in wound healing. [internet]]]></source>
<year>2016</year>
<edition>2.a ed</edition>
<page-range>201-13</page-range><publisher-loc><![CDATA[Heidelberg, Berlin ]]></publisher-loc>
<publisher-name><![CDATA[Springer]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B10">
<label>10.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yang]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Geng]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Ma]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Sun]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Fu]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Efficacy of topical recombinant human epidermal growth factor for treatment of diabetic foot ulcer: A systematic review and meta-analysis]]></article-title>
<source><![CDATA[Int J Low Extrem Wounds]]></source>
<year>2016</year>
<volume>15</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>120-5</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bui]]></surname>
<given-names><![CDATA[TQ]]></given-names>
</name>
<name>
<surname><![CDATA[Bui]]></surname>
<given-names><![CDATA[QVP]]></given-names>
</name>
<name>
<surname><![CDATA[Németh]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Hegyi]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Szakács]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Rumbus]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Epidermal growth factor is effective in the treatment of diabetic foot ulcers: Meta-analysis and systematic review]]></article-title>
<source><![CDATA[Int J Environ Res Public Health]]></source>
<year>2019</year>
<volume>16</volume>
<numero>14</numero>
<issue>14</issue>
<page-range>2584</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rahim]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Yan]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Shah]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Bibi]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Khan]]></surname>
<given-names><![CDATA[ZU]]></given-names>
</name>
<name>
<surname><![CDATA[Nawaz]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Epidermal growth factor outperforms placebo in the treatment of diabetic foot ulcer: a meta-analysis]]></article-title>
<source><![CDATA[F1000Res]]></source>
<year>2022</year>
<volume>11</volume>
<page-range>773</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zheng]]></surname>
<given-names><![CDATA[S-Y]]></given-names>
</name>
<name>
<surname><![CDATA[Wan]]></surname>
<given-names><![CDATA[X-X]]></given-names>
</name>
<name>
<surname><![CDATA[Kambey]]></surname>
<given-names><![CDATA[PA]]></given-names>
</name>
<name>
<surname><![CDATA[Luo]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Hu]]></surname>
<given-names><![CDATA[X-M]]></given-names>
</name>
<name>
<surname><![CDATA[Liu]]></surname>
<given-names><![CDATA[Y-F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Therapeutic role of growth factors in treating diabetic wound]]></article-title>
<source><![CDATA[World J Diabetes]]></source>
<year>2023</year>
<volume>14</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>364-95</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Berlanga]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Heberprot-P: experimental background and pharmacological bases]]></article-title>
<source><![CDATA[Biotecnol Apl]]></source>
<year>2010</year>
<volume>27</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>88-94</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Armstrong]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Lavery]]></surname>
<given-names><![CDATA[LA]]></given-names>
</name>
<name>
<surname><![CDATA[Harkless]]></surname>
<given-names><![CDATA[LB]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Validation of a diabetic wound classification system: The contribution of depth, infection and ischemia to risk of amputation]]></article-title>
<source><![CDATA[Diabetes Care]]></source>
<year>1998</year>
<volume>21</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>855-9</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Esquirol]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Herrero]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Factor de crecimiento epidérmico, innovación y seguridad]]></article-title>
<source><![CDATA[Med Clin]]></source>
<year>2015</year>
<volume>145</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>305-12</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Camacho]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Guillen]]></surname>
<given-names><![CDATA[IA]]></given-names>
</name>
<name>
<surname><![CDATA[Roca]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Baldomero]]></surname>
<given-names><![CDATA[JE]]></given-names>
</name>
<name>
<surname><![CDATA[Tuero]]></surname>
<given-names><![CDATA[ÁD]]></given-names>
</name>
<name>
<surname><![CDATA[Galván]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Heberprot-P&#8217;s effect on gene expression in healing diabetic foot ulcers]]></article-title>
<source><![CDATA[MEDICC Rev]]></source>
<year>2018</year>
<volume>20</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>10-4</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Çetinkaya]]></surname>
<given-names><![CDATA[Ö]]></given-names>
</name>
<name>
<surname><![CDATA[Çelik]]></surname>
<given-names><![CDATA[SU]]></given-names>
</name>
<name>
<surname><![CDATA[Erzincan]]></surname>
<given-names><![CDATA[MB]]></given-names>
</name>
<name>
<surname><![CDATA[Haz&#305;r]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Uncu]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Intralesional epidermal growth factor ap- plication is a potential therapeutic strategy to improve diabetic foot ulcer healing and prevent amputation]]></article-title>
<source><![CDATA[Turk J Surg]]></source>
<year>2020</year>
<volume>36</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>15-22</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Valenzuela-Silva]]></surname>
<given-names><![CDATA[CM]]></given-names>
</name>
<name>
<surname><![CDATA[Tuero-Iglesias]]></surname>
<given-names><![CDATA[ÁD]]></given-names>
</name>
<name>
<surname><![CDATA[García-Iglesias]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[González-Díaz]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Del Río-Martín]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Year]]></surname>
<given-names><![CDATA[IB]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[granulation response and partial wound closure predict healing in clinical trials on advanced diabetes foot ulcers treated with recombinant human epidermal growth factor]]></article-title>
<source><![CDATA[Diabetes Care]]></source>
<year>2013</year>
<volume>36</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>210-5</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fernández-Montequín]]></surname>
<given-names><![CDATA[Jl]]></given-names>
</name>
<name>
<surname><![CDATA[Valenzuela-Silva]]></surname>
<given-names><![CDATA[CM]]></given-names>
</name>
<name>
<surname><![CDATA[Díaz]]></surname>
<given-names><![CDATA[OG]]></given-names>
</name>
<name>
<surname><![CDATA[Savigne]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Sancho-Soutelo]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Rivero-Fernández]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Intra-lesional injection of recombinant human epidermal growth factor promote in advance diabetic foot ulcers multicenter, randomized, placebo-controlled, double blind study]]></article-title>
<source><![CDATA[Int Wound J]]></source>
<year>2009</year>
<volume>6</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>432-43</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yera]]></surname>
<given-names><![CDATA[IB]]></given-names>
</name>
<name>
<surname><![CDATA[Alonso]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Valenzuela]]></surname>
<given-names><![CDATA[CM]]></given-names>
</name>
<name>
<surname><![CDATA[Tuero]]></surname>
<given-names><![CDATA[AD]]></given-names>
</name>
<name>
<surname><![CDATA[Moreira]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Marrero]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Active post-marketing surveillance of the intralesional administration of human recombinant epidermal growth factor in diabetic foot ulcers]]></article-title>
<source><![CDATA[BMC Pharmacol Toxicol]]></source>
<year>2013</year>
<volume>14</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>44</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Prats]]></surname>
<given-names><![CDATA[PA]]></given-names>
</name>
<name>
<surname><![CDATA[Duconge]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Valenzuela]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Berlanga]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Edrosa]]></surname>
<given-names><![CDATA[CR]]></given-names>
</name>
<name>
<surname><![CDATA[Fernández-Sánchez]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Disposition and receptor-site binding of (125)I-EGF after topical administration to skin wounds]]></article-title>
<source><![CDATA[Biopharm Drug Dispos]]></source>
<year>2002</year>
<volume>23</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>67-76</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23.</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Barboza]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<source><![CDATA[¿Cuál es la eficacia y seguridad de HEBERPROT 75 mcg, y su lugar en la terapéutica?]]></source>
<year></year>
<publisher-name><![CDATA[Centro de Información de Medicamentos. Departamento de Farmacología y Terapéutica, Hospital de Clínicas Facultad de Medicina, Universidad de la República]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B24">
<label>24.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[García]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Febles]]></surname>
<given-names><![CDATA[SR]]></given-names>
</name>
<name>
<surname><![CDATA[Acosta]]></surname>
<given-names><![CDATA[CL]]></given-names>
</name>
<name>
<surname><![CDATA[Moliner]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Combination of the curative surgical treatment and Heberprot- P® in the neuropathic ulceration of the forefoot]]></article-title>
<source><![CDATA[Revista Cubana de Angiología y Cirugía Vascular]]></source>
<year>2015</year>
<volume>16</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>125-38</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tesar]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Szilberhorn]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Nemeth]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Nagy]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Wawruch]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Kalo]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cost-utility analysis of Heberprot-P as an add-on therapy to good wound care for patients in Slovakia with advanced diabetic foot ulcer]]></article-title>
<source><![CDATA[Front Pharmacol]]></source>
<year>2017</year>
<volume>8</volume>
<page-range>946</page-range></nlm-citation>
</ref>
<ref id="B26">
<label>26.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Romero]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Roa]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Alfonso]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Acero]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Huérfano]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Vivas-Consuelo]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cost-effectiveness analysis of the human recombinant epidermal growth factor in the management of patients with diabetic foot ulcers]]></article-title>
<source><![CDATA[Diabet Foot Ankle]]></source>
<year>2018</year>
<volume>9</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>1480249</page-range></nlm-citation>
</ref>
<ref id="B27">
<label>27.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Acosta-Reyes]]></surname>
<given-names><![CDATA[MR]]></given-names>
</name>
<name>
<surname><![CDATA[López]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Álvarez]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[González]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
<name>
<surname><![CDATA[Acosta]]></surname>
<given-names><![CDATA[AG]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Evaluación económica del uso de factor de crecimiento epidérmico recombinante humano (FCErh) en población mexicana con pie diabético en el Sector Salud]]></article-title>
<source><![CDATA[Rev Hosp Jua Mex]]></source>
<year>2014</year>
<volume>81</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>147-53</page-range></nlm-citation>
</ref>
<ref id="B28">
<label>28.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Skrepnek]]></surname>
<given-names><![CDATA[GH]]></given-names>
</name>
<name>
<surname><![CDATA[Mills]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
<name>
<surname><![CDATA[Armstrong]]></surname>
<given-names><![CDATA[DG]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Foot-in-wallet disease: tripped up by &#8220;cost-saving&#8221; reductions?]]></article-title>
<source><![CDATA[Diabetes Care]]></source>
<year>2014</year>
<volume>37</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>e196-7</page-range></nlm-citation>
</ref>
<ref id="B29">
<label>29.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Orellano]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Sánchez]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Introini]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Torre]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Torres Negreira]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Cabrera]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Costos directos en el tratamiento del pie diabético Unidad de Pie Diabético. Hospital de Clínicas. Universidad de la República]]></article-title>
<source><![CDATA[Rev Med Urug]]></source>
<year>2023</year>
<volume>39</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>e202</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
